NR3C2 and diabetes mellitus: The above findings differ from the work published by Zhang YQ et al. in China, where 76.9% of patients with type 2 diabetes mellitus received antihypertensive treatment, mainly with calcium channel blockers (26.6%) and ARB (26.6%) [42], but they are similar to those reported by Zhang J et al. in Australia, where 95.7% were on antihypertensive treatment, and of these 69% were using some RAAS blockers, including the possibility of receiving a mineralocorticoid receptor antagonist, and in this case, all were blockers of steroid origin [19, 43].